

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Highly Specialised Technology evaluation (HST)

Human alpha1-proteinase inhibitor for treating emphysema [ID856]

Draft matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • CSL Behring (human alpha1-proteinase inhibitor) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Alpha-1 Awareness UK • Alpha-1 UK Support Group • Black Health Agency • British Lung Foundation • British Liver Trust • Children’s Liver Disease Foundation • Equalities National Council • Findacure • Genetic Alliance • Jnetics • Liver4Life • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for Respiratory Technology and Physiology • Association of Genetic Nurses and Counsellors • Association of Respiratory Nurse Specialists • British Association of Dermatologists • British Geriatrics Society • British Society for Genetic Medicine • British Society of Gastroenterology • British Thoracic Society • British Transplantation Society • NHS Blood and Transplant • Primary Care Dermatology Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Chest, Heart and Stroke Scotland • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehovah’s Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS National Services Scotland • Northern Ireland Chest Heart and Stroke • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Actavis UK (budesonide, carbocisteine, salbutamol, terbutaline) • Allen & Hanbury Ltd (fluticasone) • AstraZeneca (budesonide, formoterol, symbicort, terbutaline)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health & Social Care • NHS England 	<ul style="list-style-type: none"> • Aurobindo Pahrma – Milpharm Ltd. (carbocisteine) • Boehringer Ingelheim (olodaterol, salbutamol, tiotropium) • Chiesi (beclomethasone, formoterol, fostair) • Concordia International (aminophylline) • Dr. Falk Pharma UK Ltd (budesonide) • Fannin (UK) Ltd (fluticasone, salmeterol) • Ferring Pharmaceuticals Ltd (budesonide) • Generics UK T/A Mylan (fluticasone, salmeterol) • GlaxoSmithKline (beclomethasone, fluticasone, salbutamol, salmeterol, seretide, theophylline) • Hameln pharmaceuticals limited (aminophylline) • HBS healthcare (carbocisteine) • Meda Pharmaceuticals (budesonide, fluticasone, salbutamol, theophylline) • McNeil Products Ltd (budesonide) • Merck (theophylline) • Napp Pharmaceuticals (aminophylline, fluticasone, formoterol, theophylline) • Novartis (formoterol) • Omega Pharma Ltd (beclomethasone) • Orion Pharma (beclomethasone, budesonide, formoterol, salbutamol) • Pinewood Healthcare (salbutamol) • Sandoz (budesonide, salbutamol, salmeterol) • Sanofi (carbocisteine, fluticasone) • Teva UK (beclomethasone, budesonide, fluticasone, formoterol, salbutamol, salmeterol, tiotropium) • THE BOOTS COMPANY PLC (beclomethasone, fluticasone) • Tillotts Pharma UK Limited (budesonide) • Typharm (carbocisteine) • Zentiva (carbocisteine)

Consultees	Commentators (no right to submit or appeal)
	<p data-bbox="817 318 1189 349"><u>Relevant research groups</u></p> <ul data-bbox="817 353 1401 958" style="list-style-type: none"> <li data-bbox="817 353 1114 385">• Breathing Matters <li data-bbox="817 389 1394 421">• British Association for Lung Research <li data-bbox="817 425 1219 456">• Cochrane Airways Group <li data-bbox="817 461 1401 537">• Cochrane Cystic Fibrosis and Genetic Disorders Group <li data-bbox="817 542 1305 573">• Cochrane Hepato-Biliary Group <li data-bbox="817 577 1168 609">• Cochrane Skin Group <li data-bbox="817 613 1289 645">• Foundation for Liver Research <li data-bbox="817 649 1200 680">• MRC Clinical Trials Unit <li data-bbox="817 685 1394 716">• National Institute for Health Research <li data-bbox="817 721 1353 797">• NIHR Royal Brompton Respiratory Biomedical Research Unit <li data-bbox="817 801 1369 833">• Skin Treatment and Research Trust <li data-bbox="817 837 1378 958">• University of Birmingham COPD and alpha-one anti-trypsin Deficiency Research Group <p data-bbox="817 1003 1273 1034"><u>Associated Public Health groups</u></p> <ul data-bbox="817 1039 1177 1115" style="list-style-type: none"> <li data-bbox="817 1039 1177 1070">• Public Health England <li data-bbox="817 1075 1145 1106">• Public Health Wales

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.